Form 8-K - Current report:
SEC Accession No. 0001104659-25-059366
Filing Date
2025-06-13
Accepted
2025-06-13 16:15:52
Documents
12
Period of Report
2025-06-11
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2517872d1_8k.htm   iXBRL 8-K 39922
  Complete submission text file 0001104659-25-059366.txt   206134

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA lvtx-20250611.xsd EX-101.SCH 3038
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE lvtx-20250611_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lvtx-20250611_pre.xml EX-101.PRE 22374
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2517872d1_8k_htm.xml XML 3665
Mailing Address YALELAAN 62 UTRECHT P7 3584 CM
Business Address YALELAAN 62 UTRECHT P7 3584 CM 31 6 3000 3035
LAVA Therapeutics NV (Filer) CIK: 0001840748 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40241 | Film No.: 251046778
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)